New hope for lymphoma patients who can't handle standard treatment
NCT ID NCT04189757
First seen Nov 21, 2025 · Last updated Apr 25, 2026 · Updated 26 times
Summary
This study tests a drug called acalabrutinib in people with mantle cell lymphoma who had severe side effects from the similar drug ibrutinib. The goal is to see if acalabrutinib can still shrink or control the cancer without causing the same intolerable side effects. Nine participants are being treated, and researchers are measuring how many respond to the drug and tracking any new side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.